A Physician's Perspective of RGBP
As a medical doctor, I am trained to objectively look at the clinical presentation of patients over my 30+ year career and make treatment decision that at times are a matter of life and death.
My treatment decision(s), like any doctor, can either position a patient on the road to recovery or lead to their demise. Importantly, all such decisions are based on known objective FACTS not only of a patient's medical history and clinical condition, but also on the selected pharmaceuticals for treatment. If my decisions are WRONG the patient can either get worse or DIE!
A crucial area of objective clinical assessment of patients includes the thought process of what has been proven to have a positive outcome on other patients with a similar medical history, clinical condition, and applied therapeutics.
The "take away" here is simple: FACTS MATTER!!!
Although this is not a forum for clinical evaluation of patients and treatment decisions, nevertheless objective observations based on FACTS are in play about RGBP that includes comparisons to a similar stock, ENZC.
Their similarities?? Empirically, both are Miro-Caps and both are developmental stage BioPharmas that have candidate drug Patents endeavoring to enter clinical trials for treatment evaluation of very serious medical conditions. If successful, those Patents will come to Market as Pharmaceuticals that will have a market capacity in the $Billions!
However there's a great objective separation between the two companies relative to their patent portfolio and progress:
Here's a re-cap of that comparison relative to ENZC's run to nearly $1.00 in February:
ENZC had:
#1 (1) Patent only
#2 No FDA approval
#3 No licensing arrangements
#4 No partnerships
#5 No catalysts
#6 No PR releases
#7 No prospect of revenue (due to #2 & #3)
#8 No suggestion of Buy Out by CEO
RGBP today has:
#1 24 Patents each worth $BILLIONS
#2 Licensing of (1) Patent with (2) INDs for treating pancreatic & colon cancer by mRNA Biotechnology that very clearly is The Future of Medicine
#3 FDA Approval for entering Clinical Trials is Imminent due to licensing arrangements with Oncology Pharma; a CRO that places drug patents into clinical trial venues and works proactively with the FDA for this to occur. It is very unlikely Oncology Pharma would have purchased licensing rights to that Patent if they didn't perceive it would have a very high probability of getting approved by the FDA for clinical trials.
#4 Partnership: Received up front payment from Oncology Pharma for Patent Licensing and is NOW positioned to receive Quarterly Revenues for 15 YEARS!
#5 Going Pink Current within days = Instant buying capacity on dozens of brokerage platforms World-Wide!
#6 CEO suggests Buy Out by filing an 8K on 4/27/21 to protect against a Hostile Take Over during negotiations that specifically states "negotiations must be made direct" (in reference to himself)
These are the OBJECTIVE COMPARATIVE FACTS!
Now, based on these facts, it would be reasonable to anticipate that RGBP Post-Pink Current will either match or surpass ENZC's run back in February when it hit $0.95 only 19 trading days after it went Pink Current.
To assume otherwise would require ignoring the significant fundamental differences between there two BioPharmas!
Again, FACTS MATTER!!!
I believe my comparative assessment of these two companies is reasonable, objective, and predictable based on known facts.
Lastly, Post September 28, 2021, the OTC will have a far different playing field due to the elimination of all Non-SEC compliant stocks.
This will result in a significant reduction in available stocks to invest in by the thousands.
Of the remaining stocks, the question needs to be asked how many of them will continue to be highly speculative, i.e. no business operations, no developed products or services, no operating capital, no partnerships, no prospect of revenue, etc.
I believe I just described 95% of The New OTC. As a result it would be reasonable to assume that world wide investor dollars are going to naturally flow into stocks that have lower risk with actual products, established business operations, are advanced in their development, and have a high Market Capacity like RGBP!
All of the above is a Personal Opinion only, but one that makes common sense.
I invited all feedback both pro & con.
Be well and prosper...
